Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the kinesin-5 inhibitor monastrol

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Asraf, Hila ^a   Avunie Masala, Rachel ^a   Hershfinkel, Michal ^a   Gheber, Larisa ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; KINESIN 5; MONASTROL; SMALL INTERFERING RNA; SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; KINESIN; MESSENGER RNA; PYRIMIDINE DERIVATIVE; THIOKETONE;

AGS CELL LINE; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CELL COUNT; CELL CYCLE PARAMETERS; CELL STRUCTURE; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG POTENCY; DU154 CELL LINE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEPG2 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOVO CELL LINE; MITOSIS INHIBITION; MITOTIC SLIPPAGE; PROTEIN EXPRESSION; UPREGULATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MITOSIS; NEOPLASMS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINDLE APPARATUS; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KINESIN; MITOSIS; NEOPLASMS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SPINDLE APPARATUS; THIONES; TUMOR CELLS, CULTURED;

EID: 84935007190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129255     Document Type: Article

References (58)

1. Enos AP, Morris NR. Mutation of a gene that encodes a kinesin-like protein blocks nuclear division in A. nidulans. Cell. 1990; 60(6):1019-27. PMID: 2138511
2. Hagan I, Yanagida M. Kinesin-related cut7 protein associates with mitotic and meiotic spindles in fission yeast. Nature. 1992; 356(6364):74-6. PMID: 1538784
3. Hoyt MA, He L, Loo KK, Saunders WS. Two Saccharomyces cerevisiae kinesin-related gene products required for mitotic spindle assembly. J Cell Biol. 1992; 118(1):109-20. PMID: 1618897
4. Roof DM, Meluh PB, Rose MD. Kinesin-related proteins required for assembly of the mitotic spindle. J Cell Biol. 1992; 118:95-108. PMID: 1618910
5. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995; 83(7):1159-69. PMID: 8548803
6. Kashina AS, Baskin RJ, Cole DG, Wedaman KP, Saxton WM, Scholey JM. A bipolar kinesin. Nature. 1996; 379(6562):270-2. Epub 1996/01/18. PMID: 8538794.
7. Gordon DM, Roof DM. The kinesin-related protein Kip1p of Saccharomyces cerevisiae is bipolar. J Biol Chem. 1999; 274(40):28779-86. Epub 1999/09/25. PMID: 10497250.
8. Thiede C, Fridman V, Gerson-Gurwitz A, Gheber L, Schmidt CF. Regulation of bi-directional movement of single kinesin-5 Cin8 molecules. Bioarchitecture. 2012; 2(2):70-4. PMID: 22754632.
9. Gerson-Gurwitz A, Thiede C, Movshovich N, Fridman V, Podolskaya M, Danieli T, et al. Directionality of individual kinesin-5 Cin8 motors is modulated by loop 8, ionic strength and microtubule geometry. EMBO J. 2011; 30(24):4942-54. doi: 10.1038/emboj.2011.403 PMID: 22101328; PubMed Central PMCID: PMC3243633.
10. Kapitein LC, Peterman EJ, Kwok BH, Kim JH, Kapoor TM, Schmidt CF. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature. 2005; 435(7038):114-8. PMID: 15875026.
11. Gheber L, Kuo SC, Hoyt MA. Motile properties of the kinesin-related Cin8p spindle motor extracted from Saccharomyces cerevisiae cells. J Biol Chem. 1999; 274(14):9564-72. PMID: 10092642
12. Fridman V, Gerson-Gurwitz A, Shapira O, Movshovich N, Lakamper S, Schmidt CF, et al. Kinesin-5 Kip1 is a bi-directional motor that stabilizes microtubules and tracks their plus-ends in vivo. J Cell Sci. 2013; 126(Pt 18):4147-59. doi: 10.1242/jcs.125153 PMID: 23868978.
13. Avunie-Masala R, Movshovich N, Nissenkorn Y, Gerson-Gurwitz A, Fridman V, Koivomagi M, et al. Phospho-regulation of kinesin-5 during anaphase spindle elongation. J Cell Sci. 2011; 124(Pt 6): 873-8. doi: 10.1242/jcs.077396 PMID: 21378308; PubMed Central PMCID: PMC3048887.
14. Gerson-Gurwitz A, Movshovich N, Avunie R, Fridman V, Moyal K, Katz B, et al. Mid-anaphase arrest in S. cerevisiae cells eliminated for the function of Cin8 and dynein. Cell Mol Life Sci. 2009; 66(2):301-13. PMID: 19099194. doi: 10.1007/s00018-008-8479-2
15. Fridman V, Gerson-Gurwitz A, Movshovich N, Kupiec M, Gheber L. Midzone organization restricts interpolar microtubule plus-end dynamics during spindle elongation. EMBO Rep. 2009; 10(4):387-93. PMID: 19270715. doi: 10.1038/embor.2009.7
16. Movshovich N, Fridman V, Gerson-Gurwitz A, Shumacher I, Gertsberg I, Fich A, et al. Slk19-dependent mid-anaphase pause in kinesin-5-mutated cells. J Cell Sci. 2008; 121(15):2529-39. PMID: 18628309. doi: 10.1242/jcs.022996
17. Sharp DJ, McDonald KL, Brown HM, Matthies HJ, Walczak C, Vale RD, et al. The bipolar kinesin, KLP61F, cross-links microtubules within interpolar microtubule bundles of Drosophila embryonic mitotic spindles. J Cell Biol. 1999; 144(1):125-38. PMID: 9885249.
18. Touitou I, Lhomond G, Pruliere G. Boursin, a sea urchin bimC kinesin protein, plays a role in anaphase and cytokinesis. J Cell Sci. 2001; 114(Pt 3):481-91. PMID: 11171318.
19. Saunders AM, Powers J, Strome S, Saxton WM. Kinesin-5 acts as a brake in anaphase spindle elongation. Curr Biol. 2007; 17(12):R453-4. PMID: 17580072.
20. Castillo A, Morse HC 3rd, Godfrey VL, Naeem R, Justice MJ. Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Res. 2007; 67(21):10138-47. Epub 2007/11/03. doi: 10. 1158/0008-5472.can-07-0326 PMID: 17974955.
21. Hansen GM, Justice MJ. Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B- cell leukemia. Oncogene. 1999; 18(47):6531-9. Epub 1999/12/22. doi: 10.1038/sj.onc.1203023 PMID: 10597256.
22. Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies: where they stand. Cell death & disease. 2012; 3:e411. Epub 2012/10/19. doi: 10.1038/cddis.2012.148 PMID: 23076219; PubMed Central PMCID: PMCPmc3481136.
23. Sarli V, Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14 (23):7583-7. Epub 2008/12/03. doi: 10.1158/1078-0432.ccr-08-0120 PMID: 19047082.
24. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999; 286(5441):971-4. PMID: 10542155
25. El-Nassan HB. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. European journal of medicinal chemistry. 2013; 62:614-31. Epub 2013/02/26. doi: 10.1016/j.ejmech.2013.01.031 PMID: 23434636.
26. Goulet A, Moores C. New insights into the mechanism of force generation by kinesin-5 molecular motors. International review of cell and molecular biology. 2013; 304:419-66. Epub 2013/07/03. doi: 10.1016/b978-0-12-407696-9.00008-7 PMID: 23809441.
27. Wojcik EJ, Buckley RS, Richard J, Liu L, Huckaba TM, Kim S. Kinesin-5: Cross-bridging mechanism to targeted clinical therapy. Gene. 2013; 531(2):133-49. doi: 10.1016/j.gene.2013.08.004 PMID: 23954229; PubMed Central PMCID: PMC3801170.
28. Kull FJ, Sablin EP, Lau R, Fletterick RJ, Vale RD. Crystal structure of the kinesin motor domain reveals a structural similarity to myosin. Nature. 1996; 380(6574):550-5. PMID: 8606779.
29. Sablin EP, Kull FJ, Cooke R, Vale RD, Fletterick RJ. Crystal structure of the motor domain of the kinesin-related motor ncd. Nature. 1996; 380(6574):555-9. PMID: 8606780.
30. Leizerman I, Avunie-Masala R, Elkabets M, Fich A, Gheber L. Differential effects of monastrol in two human cell lines. Cell Mol Life Sci. 2004; 61(16):2060-70. PMID: 15316655.
31. Orth JD, Tang Y, Shi J, Loy CT, Amendt C, Wilm C, et al. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther. 2008; 7(11):3480-9. Epub 2008/11/01. doi: 10.1158/1535-7163.mct-08-0684 PMID: 18974392; PubMed Central PMCID: PMCPmc2597169.
32. Silkworth WT, Cimini D. Transient defects of mitotic spindle geometry and chromosome segregation errors. Cell division. 2012; 7(1):19. Epub 2012/08/14. doi: 10.1186/1747-1028-7-19 PMID: 22883214; PubMed Central PMCID: PMCPmc3509025.
33. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Current opinion in genetics &development. 2007; 17(2):157-62. Epub 2007/02/28. doi: 10.1016/j.gde.2007.02.011 PMID: 17324569.
34. Topham CH, Taylor SS. Mitosis and apoptosis: how is the balance set? Current opinion in cell biology. 2013; 25(6):780-5. Epub 2013/07/31. doi: 10.1016/j.ceb.2013.07.003 PMID: 23890995.
35. Andreassen PR, Lohez OD, Margolis RL. G2 and spindle assembly checkpoint adaptation, and tetraploidy arrest: implications for intrinsic and chemically induced genomic instability. Mutat Res. 2003; 532 (1-2):245-53. PMID: 14643440.
36. Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr., et al. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clinical genitourinary cancer. 2008; 6(2):103-9. Epub 2008/10/01. doi: 10.3816/CGC.2008.n.016 PMID: 18824433.
37. Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, et al. A phase II study of ispinesib (SB- 715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investigational new drugs. 2008; 26(3):249-55. Epub 2007/10/27. doi: 10.1007/s10637-007-9097-9 PMID: 17962907.
38. Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational new drugs. 2008; 26(3): 257-64. Epub 2007/11/27. doi: 10.1007/s10637-007-9098-8 PMID: 18038218.
39. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell. 2012; 23(1): 1-6. Epub 2012/01/03. doi: 10.1091/mbc.E10-04-0335 PMID: 22210845; PubMed Central PMCID: PMCPmc3248889.
40. Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. International journal of molecular sciences. 2014; 15(2):2494-516. Epub 2014/02/18. doi: 10.3390/ijms15022494 PMID: 24531137; PubMed Central PMCID: PMCPmc3958864.
41. Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin-biology and potential as a therapeutic target in oncology. OncoTargets and therapy. 2013; 6:1453-62. Epub 2013/11/10. doi: 10.2147/ott.s33374 PMID: 24204160; PubMed Central PMCID: PMCPmc3804542.
42. Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol. 2012; 13(12):789-803. Epub 2012/11/24. doi: 10.1038/nrm3474 PMID: 23175282; PubMed Central PMCID: PMCPmc3729939.
43. Altieri DC. New wirings in the survivin networks. Oncogene. 2008; 27(48):6276-84. Epub 2008/10/22. doi: 10.1038/onc.2008.303 PMID: 18931693; PubMed Central PMCID: PMCPmc2683067.
44. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988; 48(17):4827-33. Epub 1988/09/01. PMID: 3409223.
45. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999; 113(6):1076-81. PMID: 10594755.
46. Jenkins VK, Barranco SC, Townsend CM Jr., Perry RR, Ives KL. Differential response to gamma radiation of human stomach cancer cells in vitro. International journal of radiation biology and related studies in physics, chemistry, and medicine. 1986; 50(2):269-78. Epub 1986/08/01. PMID: 3488285.
47. Ostlund RE Jr., Seemayer R, Gupta S, Kimmel R, Ostlund EL, Sherman WR. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3-3H]inositol. J Biol Chem. 1996; 271(17):10073-8. Epub 1996/04/26. PMID: 8626564.
48. Duhl DM, Banjar Z, Briggs RC, Page DL, Hnilica LS. Tumor-associated chromatin antigens of human colon adenocarcinoma cell lines HT-29 and LoVo. Cancer Res. 1982; 42(2):594-600. Epub 1982/02/01. PMID: 7034924.
49. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991; 51(17):4716-20. Epub 1991/09/01. PMID: 1873816.
50. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 2013; 32(10):1252-65. Epub 2012/05/15. doi: 10.1038/onc.2012.148 PMID: 22580601; PubMed Central PMCID: PMCPmc3592945.
51. Meek DW. The role of p53 in the response to mitotic spindle damage. Pathol Biol (Paris). 2000; 48(3): 246-54. PMID: 10858957.
52. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. Embo j. 2003; 22(12):2934-47. Epub 2003/06/14. doi: 10.1093/emboj/cdg307 PMID: 12805209; PubMed Central PMCID: PMCPmc162159.
53. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001; 98(2):635-40. PMID: 11149963.
54. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol. 2003; 23(16):5556-71. PMID: 12897130.
55. Matozaki T, Sakamoto C, Matsuda K, Suzuki T, Konda Y, Nakano O, et al. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochemical and biophysical research communications. 1992; 182(1):215-23. Epub 1992/01/15. PMID: 1370612.
56. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis. 1993; 14(5):987-92. Epub 1993/05/01. PMID: 8389256.
57. Pocard M, Chevillard S, Villaudy J, Poupon MF, Dutrillaux B, Remvikos Y. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene. 1996; 12(4):875-82. Epub 1996/02/15. PMID: 8632910.
58. Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, Tien Kuo M. Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochemical pharmacology. 2001; 61(5):555-63. Epub 2001/03/10. PMID: 11239498.